Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Novartis licenses Ensemble's IL-17 inhibitor, pens discovery alliance

Executive Summary

Novartis AG has licensed rights to macrocycle developer Ensemble Therapeutics Corp.’s preclinical drug candidate targeting the inflammatory cytokine IL-17. Ensemble has also agreed to use its drug discovery technologies, including DNA-Programmed Chemistry, to create small molecules against several undisclosed targets selected by Novartis.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies